Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing novel antiviral and pain-related therapies. Following its October 2024 combination, the company made Halneuron its lead program while continuing to evaluate IMC-1 and IMC-2 for herpesvirus-related disease burden, fibromyalgia, and Long-COVID-related fatigue.

2.76

2.76

— Dogwood Therapeutics, Inc.
%
Lead clinical program40% Halneuron® and related development work targeting pain and neuropathic conditions.
Antiviral combination candidates35% IMC-1 and IMC-2 fixed-dose combinations intended to suppress herpesvirus activation and replication.
Clinical development services20% Internal R&D, trial execution, and manufacturing support for pipeline advancement.
Business development and partnering5% Out-licensing, collaboration, and partnership efforts to fund and advance programs.

Dogwood does not currently sell commercial products; its primary counterparties are clinical investigators, contract...

  • Clinical development partnersprimary

    CROs, trial sites, and manufacturers that execute studies and supply drug product for Halneuron, IMC-1, and IMC-2.

  • Pharmaceutical licensing partnersprimary

    Potential partners that could fund or co-develop IMC-1 and IMC-2 in exchange for rights or economics.

  • Patients with unmet-needs indicationssecondary

    Patients with fibromyalgia, neuropathic pain, or Long-COVID fatigue who represent the eventual therapeutic market.

  • Regulatory stakeholdersprimary

    FDA and other stakeholders that determine approvable endpoints and development pathways.

The company is headquartered in the United States and appears to conduct its core operations there...

  • •United States is the operating base and headquarters market
  • •Clinical and regulatory activities are centered on U.S. development pathways
  • •No product revenue geography is disclosed because the company has none
  • •Financing activity is primarily U.S.-market based
  • •Exposure is driven more by U.S. capital markets than sales concentration

Dogwood’s strategy is to advance Halneuron as the lead program while preserving optionality on IMC-1 and IMC-2 through...

01
Secure additional financingshort-term

Cash is expected to fund operations only through the first quarter of 2026.

02
Advance Halneuron clinical developmentshort-term

Halneuron is the lead program and the main focus of day-to-day operations.

03
Partner IMC-1 and IMC-2medium-term

Partnerships can offset development costs and improve the odds of progressing programs.

Dogwood is a pre-revenue biotech with substantial going-concern risk, so its ability to fund trials is central to...

critical

Insufficient liquidity and going-concern risk

Cash on hand is expected to fund operations only through the first quarter of 2026.

Scope
All ongoing clinical trials and corporate operations
Materiality
high
high

Clinical development failure or delay

The company depends on successful trial execution to create value and attract partners.

Scope
Halneuron, IMC-1, IMC-2
Materiality
high
high

Regulatory and endpoint uncertainty

Approval pathways depend on FDA agreement on endpoints and trial design.

Scope
IMC-2 Long-COVID development
Materiality
high
high

Partnering and funding execution risk

The company needs collaboration or licensing deals to advance some programs efficiently.

Scope
IMC-1 Phase 3 partner search
Materiality
medium
medium

Dilution from future capital raises

Additional funding may come from equity or equity-linked securities.

Scope
Existing shareholders
Materiality
high
Research and development expense recognition
Affects reported burn rate and comparability across periods
Financing transaction costs
Affects cash flow presentation and equity balances
Going-concern assessment
Material disclosure affecting investor perception of solvency
Combination-related legal and professional fees
Impacts operating expense trend

Dogecoin Cash, Inc.

DOGP · Services-Personal Services

C4 Therapeutics, Inc.

CCCC · Biological Products, (No Diagnostic Substances)

NORTHWEST BIOTHERAPEUTICS INC

NWBO · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

: 28.4.2026